Trials / Unknown
UnknownNCT04812145
Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Chemoradiation | Hypofractionated radiotherapy with concurrent Gemcitabine |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-01-01
- Completion
- 2023-04-01
- First posted
- 2021-03-23
- Last updated
- 2021-03-23
Source: ClinicalTrials.gov record NCT04812145. Inclusion in this directory is not an endorsement.